IDEA AG gives an update on the development of Diractin®, the targeted analgesic - Gilde Healthcare

IDEA AG gives an update on the development of Diractin®, the targeted analgesic

28 juli 2008

Munich, Germany – IDEA AG today publicised two additional phase III clinical studies with Diractin® (ketoprofen in Transfersome® carriers, formerly known as IDEA-033) and successful completion of two long-term studies with the product.

In Q2 2008, IDEA started screening and enrolment for two additional phase III clinical trials in Europe (CL-033-III-03) and the USA (CL-033-III-06), to continue investigating the efficacy and safety of Diractin® for the treatment of osteoarthritis (OA) of the knee. In the European study, two dosages of the product are being tested against placebo and an oral comparator, celecoxib; in the USA, the study is only placebo controlled. The individual patient’s treatment period in both trials is three months. Enrolment for both studies should be finished by the end of this year. IDEA is also finalizing the analysis of a phase III, long term clinical safety and efficacy study that had been conducted in US. The study has enrolled 349 patients with OA of the knee and compared 100 mg ketoprofen in Diractin® applied epicutaneously with 500 mg naproxen given orally, both twice daily, over a treatment period of 12 months. Another study in reporting is a European phase III, open-label, long term safety and efficacy trial that had enrolled 487 patients, who were treated with Diractin® for a period of up to 36 months.

Data from both recently finished and the results from the two ongoing clinical studies with Diractin® will be used in the new application to the EMEA for Community Marketing Authorisation of the product, to be submitted in 2009.

Gregor Cevc, IDEA’s founder and CEO, commented: “After having now determined that EMEA wants to review data from all clinical studies with Diractin®, finished as well as ongoing, we will continue using best efforts to ensure their timely availability. Our present understanding of the data justifies an optimistic look forward to the final success of Diractin® both with regulators and in the marketplace, where the product could meet a large medical need.”

ENDS

For further information, please contact:

IDEA AG

Prof. Gregor Cevc PhD
CEO
Tel.: +49 (172) 8386267

Matthias Rother, MD, PhD
Exec. Head of Medical Development
Tel.: +49 (174) 1789457

Meer nieuws

Boston Scientific to Acquire Nalu Medical

We are pleased to announce the strategic exit of our portfolio company Nalu Medical. Boston Scientific, a global leader in medical technology, has agreed to acquire Gilde Healthcare portfolio company Nalu Medical at a $600m valuation....
17 oktober 2025

Gilde Healthcare company Tagworks Pharmaceuticals Announces CTA Authorization and Initiation of Phase 0/1 Clinical Trial for TGW211, a Radiopharmaceutical for the Treatment of HER2+ Tumors

TGW211 is a next-generation, first-in-class HER2-directed radioimmunoconjugate developed based on Tagworks’ proprietary Click-to-Release – bioorthogonal, in vivo click chemistry – linker platform TGW211 is designed to achieve strong tumor uptake with selective and rapid elimination...
15 oktober 2025

Gilde Healthcare company SpyGlass Pharma’s Novel BIM-IOL System Demonstrated a Statistically Significant Reduction in Mean IOP at 24 Months

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001) 100% of patients were off all topical IOP-lowering medications at 24 months 100% of treated patients achieved 20/30 or better Best Corrected Distance Visual...
14 oktober 2025